Investment Thesis
BioNexus Gene Lab Corp is operating at pre-revenue scale with only $22.8K in declining revenue while burning $147.7K annually in operations. The company exhibits unsustainable economics with negative gross margins (-3.5%) and operating margins (-2366.2%), indicating severe operational distress with no visible path to profitability. Despite holding $1.3M in cash, current burn rates suggest critical liquidity challenges within 12-24 months absent significant revenue acceleration.
Strengths
- Zero long-term debt eliminates refinancing and default risk
- Liquidity ratio of 6.52x provides near-term operational cushion
- Positive stockholders equity of $8.1M provides balance sheet foundation
Risks
- Operating cash burn of $147.7K annually with only $1.3M cash reserves creates 8-12 month runway
- Revenue declining 21.9% YoY on minuscule $22.8K base signals failed commercialization
- Negative gross margins (-3.5%) indicate unit economics are fundamentally broken, not just scale issues
- No insider transactions in 90 days suggests management may lack confidence in recovery
Key Metrics to Watch
- Quarterly revenue trend and absolute revenue level for commercialization progress
- Operating cash flow burn rate relative to cash reserves depletion timeline
- Gross margin trajectory toward positive territory indicating operational viability
Financial Metrics
Revenue
22.8K
Net Income
-543.6K
EPS (Diluted)
$-0.23
Free Cash Flow
-148.0K
Total Assets
9.0M
Cash
1.3M
Profitability Ratios
Gross Margin
-3.5%
Operating Margin
-2,366.2%
Net Margin
-2,379.7%
ROE
-6.7%
ROA
-6.0%
FCF Margin
-647.9%
Balance Sheet & Liquidity
Current Ratio
6.52x
Quick Ratio
5.69x
Debt/Equity
0.00x
Debt/Assets
10.5%
Interest Coverage
-35.25x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T07:50:42.477073 |
Data as of: 2026-03-31 |
Powered by Claude AI